MEF2C and breast carcinoma: In contrast to miR-524-5p, MEF2C was upregulated in prostate and breast cancer with bone metastasis, and the MEF2C gene was predicted to be a target for miR-631, miR-524-5p, miR-330-3p, and miR-346 (Figure 3(a)).